Previous close | 1.0800 |
Open | 1.0800 |
Bid | 0.9600 x N/A |
Ask | 1.0500 x N/A |
Day's range | 0.9500 - 1.0800 |
52-week range | 0.8000 - 3.5000 |
Volume | |
Avg. volume | 22,450 |
Market cap | 20.323M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2720 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.75 |
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it has been awarded The Emerging Life Sciences Company of the Year Award by Life Sciences British Columbia ("LSBC").
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that its CEO, Dr. James Helliwell, will present at the 2022 Bio International Convention being held at the San Diego Convention Center from June 13-16, 2022, in San Diego, CA.